Early intervention strategies to lower cardiovascular risk in early nephropathy: focus on dyslipidemia.
Patients with chronic kidney disease (CKD) are at high cardiovascular risk and we can consider them to have a risk equivalent to coronary heart disease, putting them into the high-risk category. A mixed dyslipidemia with high triglyceride levels; low high-density lipoprotein (HDL) levels; and small, dense low-density lipoprotein (LDL) particles is a common pattern in patients with CKD, contributing to their high cardiovascular disease (CVD) risk. A treatment strategy to reduce LDL cholesterol to the current high-risk category goals reduces risk similar to patients without CKD. Emerging evidence suggests that targeting non-HDL cholesterol can have the potential to bring about further CVD risk reduction. Non-HDL cholesterol should be a secondary target for all patients with CKD. Further studies are needed to determine the magnitude of the risk reduction we can expect to gain by targeting non-HDL cholesterol and the most effective way to treat this target.
Sorrentino
Matthew J
MJ
Department of Medicine, University of Chicago Pritzker School of Medicine, IL 60637, USA. msorrent@medicine.bsd.uchicago.edu
D002318:Cardiovascular Diseases / Q000150:complications* / Q000401:mortality / Q000628:therapy; D050171:Dyslipidemias / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D011507:Proteinuria / Q000150:complications* / Q000503:physiopathology / Q000652:urine; D051436:Renal Insufficiency, Chronic / Q000150:complications* / Q000188:drug therapy*; D012307:Risk Factors; D016896:Treatment Outcome